398 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 12,755 published Tirzepatide COA source records from third-party laboratories, covering 1,778 publicly attributable vendor identities. Across 11,835 records with positive numeric purity, the arithmetic mean is 99.68%. 143 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 25 positive purity results are below 90%; 598 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.50 | $5.50–$7.50 | $1.30 | 2 sources · 2 offers |
| 10 mg | $8.88 | $8.00–$9.50 | $0.89 | 4 sources · 4 offers |
| 15 mg | $9.67 | $8.50–$10.50 | $0.64 | 3 sources · 3 offers |
| 20 mg | $11.33 | $10.50–$12.00 | $0.57 | 3 sources · 3 offers |
| 30 mg | $15.00 | $12.50–$17.00 | $0.50 | 4 sources · 4 offers |
| 40 mg | $19.88 | $18.00–$23.00 | $0.50 | 4 sources · 4 offers |
| 50 mg | $22.25 | $22.00–$22.50 | $0.45 | 2 sources · 2 offers |
| 60 mg | $26.12 | $25.00–$27.50 | $0.44 | 4 sources · 4 offers |
| 100 mg | $35.00 | $35.00–$35.00 | $0.35 | 1 source · 1 offer |
| 120 mg | $37.00 | $37.00–$37.00 | $0.31 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-19T06:49:44.048537+00:00. Calculation time is not a laboratory observation date.
Within that total, 3068 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 241 | 99.6% | 0 of 229 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #2 | 195 | 99.53% | 0 of 183 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #3 | 136 | 99.78% | 0 of 96 (0.0%) 0 0% / not detected · 0 wrong compound · 40 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120707 (99.88%) · #120652 (99.93%) · #120647 (99.96%) · #120646 (99.94%) · #120710 (99.95%) · #120632 (99.9%)
This Phase 3b study represents a significant step towards developing more holistic treatment strategies for complex conditions. If successful, combining Mirikizumab and Tirzepatide could offer a novel therapeutic opti…
Tirzepatide offers a powerful new treatment option for Type 2 Diabetes Mellitus, particularly for those struggling to achieve adequate glycemic control with existing therapies. The successful completion of this Phase …
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
This study is crucial for understanding Tirzepatide's performance in patient groups often excluded from or underrepresented in randomized controlled trials. If successful, it could provide valuable evidence supporting…
If successful, this study could identify a simple, accessible, and enjoyable dietary intervention to optimize the benefits of GLP-1 therapy, potentially mitigating unwanted muscle loss and enhancing overall health out…
This review is crucial because it highlights the escalating global obesity crisis and the urgent need for novel, potentially safer, and more accessible therapeutic options. By systematically exploring natural products…
Preserving lean muscle mass is critical for maintaining metabolic health, strength, and overall quality of life during significant weight loss. If successful, this intervention could become a standard recommendation f…
Successfully demonstrating the acceptability and practicality of Tirzepatide in this population is crucial. If proven feasible, this intervention could offer a vital strategy to address obesity in breast cancer surviv…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The successful completion of this Phase 1/1b study is crucial for advancing TLC-6740 as a potential novel therapeutic agent for obesity and Type 2 Diabetes, conditions that continue to pose significant public health c…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This study holds significant promise by exploring the potential for a novel, enhanced therapeutic approach for managing complex metabolic disorders like obesity and Type 2 Diabetes. By combining a specially formulated…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
Obesity is a major comorbidity in breast cancer patients, negatively impacting treatment efficacy and increasing recurrence risk. This study is significant because it directly addresses the potential of a powerful wei…
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…
Understanding tirzepatide's effects on skeletal muscle is critically important, as preserving muscle mass during weight loss is a key challenge, especially in obesity. If tirzepatide can mitigate muscle loss or even i…
This study is crucial for understanding Tirzepatide's long-term efficacy and safety outside of highly controlled clinical trial environments. If successful, the findings could significantly inform clinical guidelines …
Understanding GIP's long-term effects on bone is critically important given the widespread use of GIP receptor (GIPR) agonists like tirzepatide for obesity and type 2 diabetes, conditions often associated with comprom…
This study holds significant promise as it could identify a new, effective pharmacological treatment for severe forms of obesity like Prader-Willi Syndrome and hypothalamic obesity, which currently have limited therap…
This study is crucial as it addresses a significant unmet need for effective anti-obesity treatments in adult congenital heart disease (ACHD) patients, a population often excluded from major clinical trials. If succes…
The discontinuation of GLP-1 agonists often leads to weight regain and a return of metabolic challenges, including elevated triglycerides, which are risk factors for cardiovascular disease. If RDX-002 proves effective…
This ongoing trial is crucial because it addresses a significant unmet medical need, potentially offering a new therapeutic option for adolescent obesity. If successful, the findings could establish tirzepatide as a s…
The study, currently underway, aims to demonstrate the significant efficacy of Tirzepatide in reducing liver fat deposition in patients with Type 2 Diabetes and NAFLD with advanced fibrosis. Based on Tirzepatide's wel…
This research is critically important as it will provide evidence-based guidance for managing incretin-based therapies in patients undergoing upper endoscopy, potentially enhancing patient safety and procedural effici…
This review highlights that obesity pharmacotherapy should be considered a disease-modifying component of Type 2 Diabetes (T2D) care, moving beyond mere weight reduction. The ability of these drugs to improve a broad …
This case report is highly significant as it identifies a potential rare but serious adverse event associated with tirzepatide use in a patient population not traditionally considered at high risk for ketoacidosis. It…
Free, no account — handy when you're working with Tirzepatide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account